Talk Bio

Sanofi-backed Expedition Therapeutics has raised an oversubscribed $115 million Series B round to advance its lead DPP1 inhibitor, EXPD-101, through a global Phase 2 trial in chronic obstructive pulmonary disease (COPD). The financing was led by General Atlantic, with new investors RA Capital and Vivo Capital joining existing backers including Sanofi Ventures, Novo Holdings, Sofinnova Investments, Forbion, and others. Expedition has just dosed the first patient in what it describes as the first global, randomized Phase 2 study of a DPP1 inhibitor for COPD, targeting neutrophilic inflammation as a key underlying driver of the disease. Sources: Sanofi-backed Expedition lands $115M for ph. 2 COPD tria Expedition raises $115m Series B to advance COPD drug A COPD drug from China draws $115M in venture funding Expedition Therapeutics' Post Expedition Therapeutics Raises $165M for COPD Therapy - LinkedIn NYSE Content Update: Expedition Therapeutics Secures ... Expediti...